About Therapy Architects
Developing novel personalized targeted leukemia therapy for children and adults
Cancer develops due to specific changes such as a mutation or phosphorylation of key molecules (target) in normal cells leading to its altered function. These changes are often patient specific. Targeted drugs associate with these molecules and destroy cancer cells. Our team of experienced cancer researchers deploy the most innovative and contemporary approaches to new drug design and are developing a proprietary targeted drug for common forms of leukemia in children and adults.
Defining mechanism of drug resistance and developing novel drugs to combat drug resistance
Patients taking a particular drug for their cancer treatment often become resistant to that drug. This resistance is due to new mutations that occur in the cancer cells. Identification and molecular characterization of these mutations is necessary to develop new drugs for these patients. Therapy architects is developing new drugs for treating drug resistance in adult leukemia.
Bioengineering novel cancer targeted drug delivery approaches
The outer surface of cancer cells has molecules designated as cancer biomarkers, that are absent in normal cells. In tumor targeted drug delivery, these unique molecules are utilized to deliver drugs specifically into cancer cells. Therapy Architects is developing nanoparticles mediated targeted drug delivery for leukemia in children and adults.
